Mctp News Archive

Using Artificial Intelligence to predict ERG Gene Fusion in Prostate Cancer
May 10, 2022

Using Artificial Intelligence to predict ERG Gene Fusion in Prostate Cancer

The role of artificial intelligence (AI) in healthcare continues to expand. In a recent issue of BMC Cancer, Dr. Vipulkumar Dadhania (first author) and colleagues published a result of their study Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. The expert team from the Michigan Center for Translational Pathology developed a deep-learning-based model to predict ERG genomic rearrangements in prostatic adenocarcinomas using only H&E-stained digital slides [...]

Parolia Selected For Harold Weintraub Graduate Student Award
Mar 1, 2022

Parolia Selected For Harold Weintraub Graduate Student Award

Please join us in congratulating Dr. Abhijit Parolia on being selected for the 2022 Harold Weintraub Graduate Student Award. The award, established by the Fred Hutchinson Cancer Research Center, is given yearly and recognizes outstanding achievement during graduate studies in the biological sciences [...]

Arul Chinnaiyan, MD, PhD, selected for the Sjöberg Prize in Cancer Research
Feb 11, 2022

Arul Chinnaiyan, MD, PhD, selected for the Sjöberg Prize in Cancer Research

The Royal Swedish Academy of Sciences, which also awards the Nobel Prizes, announced today that Arul Chinnaiyan, MD, PhD, S.P. Hicks Professor of Pathology and Urology at Michigan Medicine and Director of the Michigan Center for Translational Pathology, has been selected as [...]

Study Demonstrates a Novel Approach to Target Enhancer-Addicted Cancers
Jan 4, 2022

Study Demonstrates a Novel Approach to Target Enhancer-Addicted Cancers

A chromatin degrader stops transcription factors from driving cancer, which may serve as a potential treatment approach for over 90% of prostate cancers.

Inside the COVID Pandemic: A Laboratory Perspective
Nov 29, 2021

Inside the COVID Pandemic: A Laboratory Perspective

The SARS-CoV-2 virus brought lab testing to the headlines. Learn how Michigan Medicine Pathology responded to this unprecedented challenge.

TRIM63 - What is it?  (Hint:  Not a weight-loss product)
Aug 9, 2021

TRIM63 - What is it? (Hint: Not a weight-loss product)

Dr. Xiao-Ming (Mindy) Wang and colleagues from the Michigan Center for Translational Pathology and Department of Pathology published a groundbreaking finding from an inter-institutional study regarding TRIM63 in Modern Pathology  [...]

Researchers Uncover Way to Harness the Power of Immunotherapy for Advanced Prostate Cancer
Aug 3, 2021

Researchers Uncover Way to Harness the Power of Immunotherapy for Advanced Prostate Cancer

Findings offer clues to why some types of renal cell carcinoma respond to immunotherapy while others do not — it’s a scientific riddle tangled up in a complex web. How do you turn an immune cold cancer into one that responds to immunotherapy?

Analysis Reveals How Kidney Cancer Develops and Responds to Treatment
Jun 10, 2021

Analysis Reveals How Kidney Cancer Develops and Responds to Treatment

Not all kidney cancers behave the same, with wildly different responses to immunotherapy or other treatments – and wildly different outcomes for patients as a result. By sequencing the RNA of individual cells within multiple benign and cancerous kidney tumors, researchers from the University of Michigan Rogel Cancer Center have identified the cells [...]

Study Suggests Path to Blocking Common Genetic Driver of Lung Cancer
May 12, 2021

Study Suggests Path to Blocking Common Genetic Driver of Lung Cancer

Stopping the interaction between KRAS and the protein AGO2 slowed tumor growth in mouse models.

Arul Chinnaiyan, MD, PhD, Recognized for Outstanding Research
May 7, 2021

Arul Chinnaiyan, MD, PhD, Recognized for Outstanding Research

Congratulations to Arul Chinnaiyan, MD, PhD, who was announced as the Science of Oncology Award and Lecture recipient by the American Society of Clinical Oncology (ASCO). As part of this award, Chinnaiyan will present a 30-minute lecture entitled “Exploring Precision Oncology: from Gene Fusions to Related Genetic Drivers“ at the ASCO Annual Meeting, to be held virtually on June 4-8, 2021 [...]

Arul Chinnaiyan, MD, PhD Recognized for Outstanding Research
May 3, 2021

Arul Chinnaiyan, MD, PhD Recognized for Outstanding Research

Congratulations to Arul Chinnaiyan, MD, PhD, who was announced as the Science of Oncology Award and Lecture recipient by the American Society of Clinical Oncology (ASCO). As part of this award, Chinnaiyan will present a 30-minute lecture entitled “ “ at the ASCO Annual Meeting, to be held virtually on June 4-8, 2021.

Biomarker Could Help Identify Difficult-to-Diagnose Kidney Cancer Subtype
Apr 14, 2021

Biomarker Could Help Identify Difficult-to-Diagnose Kidney Cancer Subtype

MiTF renal cell carcinoma can masquerade as other subtypes and may not respond as well to front-line therapies.

New Assay For Early Detection of Aggressive Prostate Cancers Developed
Apr 13, 2021

New Assay For Early Detection of Aggressive Prostate Cancers Developed

A new study, led by U-M graduate in molecular and cellular pathology Dr. Andi Cani, was just published in European Urology Oncology. The publication focuses on the development of a whole-urine, multiplexed, next-generation RNA-sequencing assay that is used for the early detection of aggressive forms of prostate cancer [...]

How Useful is Next-Generation Sequencing for Patients with Advanced Cancer?
Apr 8, 2021

How Useful is Next-Generation Sequencing for Patients with Advanced Cancer?

Patients with cancers of unknown origin greatly benefited from next-generation sequencing; widespread inherited cancer risk also suggests broad utility, a study finds.

"A Correct Diagnosis Can Be Life-Changing": Dr. Rohit Mehra
Mar 9, 2021

"A Correct Diagnosis Can Be Life-Changing": Dr. Rohit Mehra

Dr. Mehra discusses his career path and how he arrived at Michigan Medicine in our latest Careers in Pathology video.

Stressed Cellular Protein HOPS Into Action
Feb 16, 2021

Stressed Cellular Protein HOPS Into Action

Research team discovered that proteins with the capacity to multimerize quickly responded to osmotic changes (dehydration) caused by high saline or sugar concentrations, condensing into aggregates resembling processing bodies (P-bodies). The reaction, known as hyperosmotic phase separation, or HOPS, takes only a few seconds and is reversible within less than 2 minutes [...]

Research from Dr. Udager Published in European Urology
Feb 1, 2021

Research from Dr. Udager Published in European Urology

A new publication, generated by Department of Pathology faculty members Drs. Aaron Udager and Scott Tomlins was successfully published in European Urology. The research highlights a longitudinal cohort study centered around the serial molecular profiling of low-grade prostate cancer in order to better assess tumor upgrading [...]

Prostate Cancer Regulator Plays Role in COVID-19, Providing a Promising Treatment Lead
Dec 22, 2020

Prostate Cancer Regulator Plays Role in COVID-19, Providing a Promising Treatment Lead

Clinical trials underway are testing whether drugs that target the androgen receptor – successful in controlling prostate cancer – could also work against the coronavirus. wo proteins, ACE2 and TMPRSS2, help the coronavirus gain entry and replicate within cells. TMPRSS2 is well-known to Arul Chinnaiyan, MD, PhD. His lab discovered that TMPRSS2 fuses with the ETS gene to drive more than half of all prostate cancers [...]

Research Regarding Microcystic Adnexal Carcinomas Published
Jun 11, 2020

Research Regarding Microcystic Adnexal Carcinomas Published

The research was just published in Modern Pathology and highlights the importance of next-generation sequencing within oncogenic roles for P53 and JAK/STAT signaling in microcystic adnexal carcinomas.

U-M Researchers Home in on Key Player in Pancreatic Cancer Development
Jun 4, 2020

U-M Researchers Home in on Key Player in Pancreatic Cancer Development

The protein Argonaute 2 was found to be critical to the progression from benign lesions into pancreatic cancer, suggesting a therapeutic opportunity.